{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'the 5 hours postdose assessments after IV administration and the 3 hours postdose assessments', \"after the first and second SC injections and with the Investigator's approval.\", '8.3.8', 'Disease-related Events and/or Disease-related Outcomes Not Qualifying as', 'AEs or SAEs', 'The following disease-related events (DREs) are common in subjects with GPP and can be', 'serious/life-threatening:', 'Flare of GPP.', 'Because these events are typically associated with the disease under study, they will not be', 'reported according to the standard process for expedited reporting of SAEs even though the', 'event may meet the definition of a SAE. These events will be recorded on the corresponding', \"eCRF page in the subject's eCRF.\", 'NOTE: If either of the following conditions applies, then the event must be recorded and', 'reported as an SAE (instead of a DRE):', \"The event is, in the Investigator's opinion, of greater intensity, frequency, or duration than\", 'expected for the individual subject.', 'OR', 'The Investigator considers that there is a reasonable possibility that the event was related to', 'study treatment.', '8.4', 'Treatment of Overdose', 'For this study, any dose of ANB019 >750 mg/', 'within a 24-hour time period on Day 1', 'and >100 mg on Days 29, 57, and 85 will be considered an overdose.', 'In the improbable event of a suspected overdose, the following procedures should be executed:', 'Administration is to be discontinued.', 'The subject is to be monitored clinically.', 'Supportive measures are to be undertaken as clinically indicated.', 'Electrocardiography and clinical laboratory evaluations (ie, blood glucose, hepatic enzymes,', 'creatinine, blood urea nitrogen, creatine kinase, and complete blood count) are to be', 'performed and followed until all values return to baseline levels and AEs subside.', 'Sponsor does not recommend specific treatment for an overdose.', 'In the event of an overdose, the Investigator should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the subject for any AE/SAE and laboratory abnormalities and follow-', 'up until resolution.', '29 October 2019', '44']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '3. Obtain a serum sample for PK analysis within 24 hours from the date of the last dose', 'of study treatment if requested by the Medical Monitor (determined on a case-by-case', 'basis).', '4. Document the quantity of the excess dose as well as the duration of the overdose in the', 'eCRF.', 'Decisions regarding dose interruptions or modifications will be made by the Investigator in', 'consultation with_the Medical Monitor based on the clinical evaluation of the subject.', '8.5', 'Pharmacokinetics', 'Whole blood will be obtained for the determination of ANB019 in human serum. Samples will', 'be collected according to the schedule presented in Section 1.3. Approximately 65 mL total of', 'whole blood will be obtained from each subject for PK assessments during the study. Each serum', 'sample will be divided into 2 aliquots (1 each for primary and a back-up). Samples collected for', 'analyses of ANB019 serum concentration may also be used to correlate exposure to safety or', 'efficacy aspects related to concerns arising during or after the study.', 'The actual date and time (24-hour clock) of the blood sample collection will be recorded in the', \"subject's eCRF. The details of blood sample collection, sample tube labeling, sample\", 'preparation, storage, and shipping procedures will be described in a separate Laboratory Manual.', 'The measurement of the concentrations of ANB019 will be performed using a validated assay', 'method. The analytical methods used to measure concentrations of ANB019 will be described in', 'a separate bioanalytical report. Only samples which are within the stability window of the', 'bioanalytical assay will be analyzed.', '29 October 2019', '45']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Table 2', 'PK/ADA Sample Collection and Timepoints', 'PK Sample Timepoint', 'ADA Sample Timepoint', 'Study Visit', 'Plasma', 'Serum', 'Predose', 'Predose', 'Day 1a', '1 hr ( 10 min) postdose', '4 hrs ( 10 min) post-dose', 'Day 3', 'Anytime', 'Day 8', 'Anytime', 'Day 15', 'Anytime', 'Day 22', 'Anytime', 'Day 29', 'Predose', 'Predose', 'Day 43', 'Anytime', 'Day 57', 'Predose', 'Predose', 'Day 71', 'Anytime', 'Day 85', 'Predose', 'Predose', 'Day 113', 'Anytime', 'Day 141', 'Anytime', 'Day 169', 'Anytime', 'Anytime', 'ADA = anti-drug antibodies; hr(s) = hour(s); min = minutes; PK = pharmacokinetic.', 'a Infusion of study treatment will take approximately 1 hour. Therefore, the 1-hour PK sample collection on Day 1', 'must start immediately at the end of the infusion. The 4-hour collection must occur exactly 3 hours after the 1-hour', 'collection is completed.', '8.6', 'Pharmacodynamics', 'Pharmacodynamic parameters will not be evaluated in this study.', '8.7', 'Genetics', 'Pharmacogenomic testing is optional and voluntary. For those patients who signed the original', 'pharmacogenomics ICF, a whole blood sample will be collected at the study visit as specified in', 'the study flow chart and this sample will be stored for future analysis. Specific procedures for', 'storage and shipping of pharmacogenomic samples will be provided in a lab manual.', 'DNA testing will be performed only at Day 1. Ribonucleic acid (RNA) testing will be performed', 'on Day 1 and Week 16. The DNA and RNA samples may be used to determine a possible', 'relationship between genes and response to treatment with ANB019 and possible side effects to', 'ANB019. Genes that may be studied will be identified later as these are for exploratory purposes.', 'These prepared samples will be transferred to the pre-identified lab that will, on behalf of', 'AnaptysBio, extract DNA and RNA from the samples (See Appendix 7 for information', 'regarding genetic research). Details on processes for collection and shipment and destruction of', 'these samples can be found in a separate Laboratory Manual.', '8.8', 'Biomarkers', 'Samples will be collected according to the schedule presented in Section 1.3 to measure skin', 'biopsy biomarkers. Measurements may include but are not limited to immunohistochemistry and', 'Reverse Transcription Polymerase Chain Reaction to assess psoriasis associated markers of', '29 October 2019', '46']\n\n###\n\n", "completion": "END"}